Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial

被引：0
|
作者：
Jiang, Y-F. [1 ]
Bei, W-X. [1 ]
Wang, L. [2 ]
Xu, C. [2 ]
Lu, N. [3 ]
Liang, H. [4 ]
Ke, L-R. [3 ]
Ye, Y-F. [5 ]
Fang, T. [1 ]
He, S. [6 ]
Dong, S-H. [1 ]
Liu, Q. [1 ]
Zhang, C. [1 ]
Xia, W. [1 ]
Zhao, C. [1 ]
Xie, C. [7 ]
Liu, G. [8 ]
Xiang, Y-Q. [1 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, Dept Radiol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[5] Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Radiat Oncol, Guang Zhou, Peoples R China
[7] NCI, Thorac & GI Malignancies Branch, Bethesda, MD USA
[8] Sun Yat Sen Univ, Radiotherapy Dept, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
893P
引用
收藏
页码：S633 / S634
页数：2
相关论文
共 50 条
  • [21] Tebotelimab, a PD1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study
    Lu, Si
    Chen, Yu
    Fang, Meiyu
    Zou, Zhengyun
    Wu, Di
    Luo, Zhiguo
    Zhang, Jian
    Chen, Jing
    Huang, Gang
    Pan, Hongming
    Ren, Xiubao
    Cheng, Ying
    Su, Haichuan
    Xin, Yuan
    Hua, Qiong
    Hou, Jianmei
    Guo, Jun
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study
    Xu, R.
    Wang, F. H.
    Feng, F. J.
    Li, Q.
    Xu, N.
    Hu, X. C.
    Liao, W. J.
    Jiang, Y.
    Lin, X.
    Zhang, Q. Y.
    Yuan, X. L.
    Huang, H. X.
    Chen, Y.
    Dai, G. H.
    Shi, J. H.
    Shen, L.
    Ren, C.
    Wu, H.
    Feng, H.
    Yao, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] GLS-010 (ZIMBERELIMAB), A NOVEL FULLY HUMAN ANTI-PD-1 MAB IN CHINESE PATIENTS WITH RECURRENT/METASTATIC CERVICAL CANCER: RESULTS FROM A MULTICENTER, OPEN-LABEL, SINGLE-ARM PHASE II TRIAL
    Wu, X.
    Xia, L.
    Zhou, Q.
    Zhu, J.
    Wang, K.
    Chen, J.
    Huang, Y.
    Kurb, G.
    Chang, B.
    Zhao, W.
    Wang, X.
    Yang, Y.
    Lin, Z.
    Luo, X.
    Lou, G.
    Wang, C.
    Wang, J.
    Meng, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A147 - A147
  • [24] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study.
    Sheng, Xinan
    Chen, Haige
    Yao, Xin
    Hu, Yi
    Yao, Xudong
    Liu, Ziling
    Zhou, Fangjian
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [26] A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer
    Yang, Chunxu
    Sun, Shaoxing
    Xiang, Qingming
    Chen, Min
    Mei, Zijie
    Wu, Qiuji
    Qiu, Hui
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S290 - S290
  • [27] A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas
    Wilky, Breelyn A.
    Maleddu, Alessandra
    Mailhot, Anne
    Cartwright, Chelsey
    Gao, Dexiang
    Tellez, Cristiam Moreno
    Powers, Kyle
    Kemp, Lindsey
    Therrien, Nicholas
    Patel, Jaymin M.
    Grossman, Joseph Elan
    O'Day, Steven
    Elias, Anthony D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.
    Wang, Fenghua
    Wei, Xiao-Li
    Feng, Ji Feng
    Li, Qi
    Xu, Nong
    Hu, Xi-Chun
    Jiang, Yi
    Liao, Wangjun
    Zhang, Qingyuan
    Yuan, Xianglin
    Huang, Haixin
    Chen, Ye
    Dai, Guanghai
    Shi, Jianhua
    Shen, Lin
    Yang, Shujun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Tislelizumab (Anti-PD-1) combined with definitive chemoradiotherapy in recurrent and/or metastatic cervical cancer (PILOT-2020-511): A single-arm, phase II trial
    Zhu, J.
    Ke, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S520 - S520
  • [30] Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
    Chen, Gang
    Sun, Dong-Chen
    Ba, Yi
    Zhang, Ya-Xiong
    Zhou, Ting
    Zhao, Yuan-Yuan
    Zhao, Hong-Yun
    Fang, Wen-Feng
    Huang, Yan
    Wang, Zhen
    Deng, Chao
    Hu, De-Sheng
    Wang, Wei
    Lin, Jin-Guan
    Li, Gui-Ling
    Luo, Su-Xia
    Fu, Zhi-Chao
    Zhu, Hai-Sheng
    Wang, Hui-Li
    Cai, Sheng-Li
    Kang, Xiao-Qiang
    Zhang, Li
    Yang, Yun-Peng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
12345